Core Viewpoint - Rite Aid is closing an additional 114 stores as part of its second bankruptcy proceedings in less than two years, driven by mounting debt, sluggish sales, and competition in the pharmacy industry [1][3][4]. Group 1: Bankruptcy and Store Closures - Rite Aid filed for Chapter 11 bankruptcy protection in May 2023, just eight months after exiting its first bankruptcy [2][4]. - The bankruptcy court in New Jersey approved the closure of 114 stores, with the majority located in Pennsylvania [1][2][7]. - The company has already closed 154 stores as part of its store optimization plan, reducing its footprint to approximately 1,245 locations [3][4]. Group 2: Financial Challenges - Rite Aid emerged from its first bankruptcy with $2.5 billion in liabilities, indicating ongoing financial struggles [4]. - The company has faced increased competition from other pharmacy chains such as Walgreens, CVS, Walmart, and Amazon, which has contributed to its financial difficulties [4][6]. Group 3: Industry Context - Industry experts anticipate further closures across the pharmacy sector as companies adjust to market demands and rightsize their operations [6]. - The rapid expansion of pharmacy locations has outpaced the actual need for pharmacies, leading to financial strain on companies like Rite Aid [6].

Capital Restructuring - Walgreens Boots is initiating a multi-currency debt tender as part of its capital restructuring [1] - This follows banks offloading a $45 billion debt package [1] Acquisition Financing - The debt package was used to finance Sycamore's buyout of the Boots pharmacy chain [1]

Core Points - PharmaCorp RX Inc. has agreed to acquire a 100% interest in a PharmaChoice Canada bannered pharmacy business for a purchase price of $2,400,000, expected to close around July 31, 2025 [1][2] - The acquisition will be funded using cash on hand and is subject to customary adjustments and a net asset value adjustment as of the closing date [1] - The company currently operates three PharmaChoice bannered pharmacies and plans to continue acquiring more as part of its strategic alliance with PharmaChoice Canada [2] Company Strategy - The acquisition reflects PharmaCorp's strategic alliance with PharmaChoice Canada and its disciplined acquisition strategy [2] - The company sees strong opportunities for growth and intends to remain active in pursuing further acquisitions in the coming months [2] - PharmaCorp will also consider acquiring independently owned non-PharmaChoice Canada bannered pharmacies and operate them under the PharmaChoice Canada banner [2]

Market Position and Growth - Guardian Pharmacy Services is a market leader in the Assisted Living Facility (ALF) market with a 13% market share[12] - The company serves over 189,000 residents[12] - The company has 32 pharmacies with > 40% Market Share[16] - The company has 12 pharmacies as Market Share Leader[16] - The company has 11 states with > 25% Market Share[15] - The company's revenue has grown at a CAGR of 15.8% from 2012 to 2024[19] Financial Performance - Adjusted EBITDA in 2024 was $90.834 million[60] - The company's Insurance Optimizer program resulted in ~$41 million in savings, or ~$514 per resident, for ~79,000 residents with claims[52] Acquisition Strategy - The company targets acquisitions with ~$10 - $30 million in revenue and ~2,000 - 3,500 residents[23] - Acquired pharmacies demonstrate strong revenue and resident growth after integration with Guardian[30]

Core Insights - PharmaCorp Rx Inc. reported a net income of $254,000 for Q1 2025, marking its first quarter of positive net income [2][3] - The company has entered into non-binding letters of intent to acquire four community pharmacies for approximately $12.5 million, aligning with its acquisition-driven growth strategy [5][6] Financial Performance - Same-store sales increased by 4.0% year-over-year compared to Q1 2024, indicating organic growth across the pharmacy network [3] - Total prescription volumes rose by 3.2% year-over-year, reflecting sustained patient engagement [4] Acquisition Strategy - The proposed acquisitions are expected to be accretive to earnings and will be funded through a combination of cash and common shares [5][6] - The completion of these acquisitions is subject to the execution of definitive agreements and customary conditions, with anticipated closings between June 30 and August 31, 2025 [7] Operational Outlook - The company remains committed to expanding its national footprint through strategic acquisitions and operational excellence [9] - Management expresses confidence that the momentum from Q1 results will continue to build in future quarters [3][9]

Financial Data and Key Metrics Changes - Revenue for Q1 2025 was reported at $329 million, reflecting a 20% year-on-year increase [5][12] - Resident count increased by 15% year-on-year, reaching approximately 189,000 [5][12] - Adjusted EBITDA for the quarter was $23.4 million, a 16% increase compared to the previous year [5][12] - Excluding PUBCO costs, adjusted EBITDA growth was 20% year-on-year [12] Business Line Data and Key Metrics Changes - The growth in revenue was driven by organic growth and acquisitions, specifically from Heartland and Freedom pharmacies [12] - Gross profit increased to $64.4 million, representing a 17% increase [12] Market Data and Key Metrics Changes - The company is actively monitoring industry trends, particularly the impact of tariffs and the Inflation Reduction Act [9][10][11] Company Strategy and Development Direction - The company is focused on sustainable long-term value creation for shareholders and is committed to integrating multiple acquisitions [5][6] - An acquisition of a small pharmacy in Wichita, Kansas was completed, increasing the total number of pharmacies to 52 [6] - The company is expanding its regional presence through Greenfield startups and acquisitions [8][20] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in navigating potential impacts from the Inflation Reduction Act and tariffs, indicating a robust acquisition pipeline [10][11][38] - The company expects to end the year in the upper half of its revenue guidance range due to strong Q1 performance [5][15] Other Important Information - The company ended Q1 with $14 million in cash and zero debt, maintaining a strong financial position [15] - The integration of Heartland's IT infrastructure is underway, which may impact profitability in the short term but is expected to enhance long-term success [13][14] Q&A Session Summary Question: Size of Heartland drag in Q1 and full year integration costs - Management indicated that the integration costs were included in guidance, with approximately $500,000 pulled into Q1 due to expedited operating system conversion [25] Question: Impact of the Trump executive order on payer negotiations - Management noted uncertainty regarding the executive order's effects but remains positive about ongoing discussions with payors [26][27] Question: Breakdown of resident count growth between same-store metrics and acquisitions - Management confirmed that organic growth met guidance, with the remainder attributed to acquisitions [36] Question: Pipeline status and impact of economic uncertainty - Management reported a robust acquisition pipeline, indicating that economic pressures have not negatively impacted opportunities [38]

That's up from 4,300 in October 2023 and 4,800 in February. During that month, these centers handled 40% of the prescription volume on average at supported pharmacies, which translates to roughly 16 million prescriptions filled per month at the different sites, the company said. "Right now, they're the backbone to really help us offset some of the workload in our stores, to obviously allow more time for our pharmacists and technicians to spend time with patients," Rick Gates, Walgreens' chief pharmacy offic ...

Core Insights - PharmaCorp RX Inc. has successfully completed the acquisition of a pre-1954 charter company in Ontario, allowing it to operate pharmacies in the region [1][2] - The acquisition is significant as it enables PharmaCorp to bypass ownership restrictions under the Drug and Pharmacies Regulations Act (Ontario), which limits non-pharmacist owned corporations from operating pharmacies [2] - PharmaCorp currently operates three PharmaChoice bannered pharmacies and plans to continue acquiring more pharmacies under the PharmaChoice Canada brand [3] Company Overview - PharmaCorp operates under the TSX Venture Exchange with the symbol PCRX and is focused on expanding its pharmacy operations in Canada [3] - The company aims to acquire both PharmaChoice Canada branded pharmacies and independently owned non-PharmaChoice Canada bannered pharmacies, integrating them into its operations [3]

Group 1 - PharmaCorp Rx Inc. has filed its audited financial statements and associated MD&A for the year ended December 31, 2024, on SEDAR+ [1] - The company operates three PharmaChoice bannered pharmacies in Canada and plans to acquire more as they become available [2] - PharmaCorp intends to acquire independently owned non-PharmaChoice Canada bannered pharmacies and operate them under the PharmaChoice Canada banner [2] Group 2 - PharmaCorp shares are traded on the TSX Venture Exchange under the symbol PCRX [2]

"Pharmacies have a legal responsibility to prescribe controlled substances in a safe and professional manner, not dispense dangerous drugs just for profit," Attorney General Pamela Bondi said in a statement. "This Department of Justice is committed to ending the opioid crisis and holding bad actors accountable for their failure to protect patients from addiction." WALGREENS SUED BY DOJ, ALLEGING IT KNOWINGLY FILLED ILLEGAL PRESCRIPTIONS INCLUDING 'DANGEROUS' OPIOIDS Walgreens has agreed to pay up to $350 mi ...